Melanotan-2: A Literature Course on What Studies Report

Course overview

This course summarises what the published literature contains about Melanotan-2 (also written melanotan II or MT-II) and about the melanocortin receptor system it targets. It is organised into six modules, each closing with an explicit statement of what the evidence cannot support, followed by a section on what the studies did not test. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. No dosing schedules, administration routes or protocols are reproduced anywhere on this page, because the verified sources summarised here do not provide a human dosing evidence base.

One structural point shapes every module: in the literature gathered for this course, there are no controlled human efficacy trials of Melanotan-2. What exists is (a) pharmacology describing the compound as a research tool, (b) animal work on melanocortin receptor activation more broadly, and (c) clinical case reports describing harms in people who obtained unlicensed products. Readers should hold those three categories apart, because they carry very different weight.

Module 1 — What Melanotan-2 is and how it has been studied

Definition and class. Melanotan-2 is a synthetic, cyclic peptide analogue of α-melanocyte-stimulating hormone (α-MSH), a member of the melanocortin family of signalling peptides. It is classified pharmacologically as a non-selective agonist across melanocortin receptor subtypes, and a 2024 pharmacology paper recommending tool compounds for the melanocortin receptor G protein-coupled receptors listed melanocortin agonists and antagonists of this type as reference ligands for laboratory characterisation of MCR signalling (PMID 39296259). That framing is important: the compound entered the literature as an experimental probe of receptor biology, not as a candidate cosmetic product.

Origin. The melanocortin field grew out of work on α-MSH and pro-opiomelanocortin (POMC) biology. Studies of that pathway continue today — for example, researchers reported that hypothalamic POMC deficiency increased circulating adiponectin despite obesity in a rodent model, illustrating how central melanocortin signalling is dissected genetically rather than only pharmacologically (PMID 32244188).

Forms encountered in the literature. Clinical publications describe Melanotan-2 as an injectable product obtained outside regulated medical supply. A 2019 case report described priapism in a man after melanotan use undertaken for tanning purposes (PMID 30796078), and a 2020 case report with literature review described renal infarction as a possible consequence of melanotan II exposure (PMID 31953620). Separately, a 2017 review of self-tanning and sunless tanning products surveyed the products and practices used to obtain pigmentation without ultraviolet exposure (PMID 28823805), and a 2022 qualitative review examined misinformation and conspiracy theories circulating in the skin cancer space (PMID 35514125).

Limits of the evidence in Module 1

The sources establish what the molecule is and the contexts in which it has been documented. They do not establish product identity, purity or content for any material described in case reports, and none of them characterises a standardised pharmaceutical formulation of Melanotan-2.

Module 2 — Mechanism as described in the literature

The mechanistic account in published work runs through the melanocortin receptors, a family of G protein-coupled receptors (MC1R–MC5R) with distinct tissue distributions. The 2024 tool-compound paper described these receptors as a GPCR family for which carefully selected agonists and antagonists are needed to interpret experiments, and it framed non-selective ligands as compounds that engage several subtypes at once (PMID 39296259). That non-selectivity is the central mechanistic claim for Melanotan-2 in the literature, and it is also the reason effects are described as multi-system rather than confined to pigmentation.

Pigmentary signalling

MC1R signalling in melanocytes is the pathway associated with melanin production, and the 2017 review of self-tanning and sunless tanning products discussed the broader category of approaches used to achieve pigmentation without sun exposure (PMID 28823805).

Central melanocortin signalling

Most melanocortin literature concerns central MC3R/MC4R signalling in energy balance and autonomic control. Researchers reported that inherently lean rats showed enhanced activity and skeletal muscle responses to central melanocortin receptor stimulation compared with the comparison animals in that study (PMID 29566460). A 2021 study reported that long-term activation of the central nervous system leptin–melanocortin system restored cardiac function after myocardial infarction in the model used (PMID 33532666), and a 2024 report examined therapeutic strategies aimed at metabolic imbalance in a male mouse model with 5-HT2CR loss of function, a model in which serotonergic input onto melanocortin neurons is disrupted (PMID 38815086).

Immunomodulatory signalling

Melanocortin peptides also have described anti-inflammatory actions. Researchers reported that melanocortin receptor agonists suppressed experimental autoimmune uveitis in the animal model studied (PMID 35196505).

Sexual function signalling

Central melanocortin activation has long been discussed in the erectile dysfunction literature, and a 2003 review of erectile dysfunction therapy surveyed the pharmacological approaches under discussion at the time (PMID 14569381). The clinical mirror image of that mechanism appears in the priapism case report (PMID 30796078).

Limits of the evidence in Module 2

Mechanistic plausibility is not outcome evidence. Receptor pharmacology and rodent models explain why effects across pigment, appetite, cardiovascular and sexual systems are biologically conceivable; they do not quantify any of those effects in humans, and several of the cited studies used genetic models or unnamed melanocortin agonists rather than Melanotan-2 itself.

Module 3 — Reported outcomes by study

The table below summarises the model, endpoint and reported direction of finding for the experimental studies in this course. Each entry links to the source record.

On the human side, the reported outcomes are clinical events rather than efficacy endpoints. A case report described priapism following melanotan use (PMID 30796078), and a case report with accompanying literature review described renal infarction as a possible consequence of melanotan II exposure (PMID 31953620).

Limits of the evidence in Module 3

No outcome in this module should be read as a benefit of Melanotan-2 in people. The animal findings concern melanocortin pathway activation in specific disease models with small group sizes and species-specific physiology, and effects observed in a rodent infarction or uveitis model do not transfer to human pigmentation, body weight or sexual function. There is no dose–response curve, no comparator drug and no human efficacy endpoint anywhere in this evidence set.

Module 4 — Melanotan-2 Side Effects: What Studies Report

The published human record for Melanotan-2 is dominated by adverse events, and each of the following statements is drawn from the specific report cited alongside it.

• Priapism. A 2019 case report in BMJ Case Reports described melanotan-induced priapism in a man who had used the peptide for tanning (PMID 30796078).
• Renal infarction. A 2020 case report with literature review described melanotan II as a possible cause of renal infarction, placing the case alongside previously published melanotan-associated events (PMID 31953620).
• Unregulated tanning practice context. The 2017 review of self-tanning and sunless tanning products surveyed the safety considerations attached to products used to obtain colour without ultraviolet exposure (PMID 28823805).
• Information environment. A 2022 qualitative review characterised misinformation and conspiracy theories circulating about skin cancer, a relevant backdrop for claims made about tanning peptides (PMID 35514125).

Because central melanocortin activation has cardiovascular and autonomic components, the vascular event described in the renal infarction report has been discussed in the context of the pathway's broad reach (PMID 31953620), while the erectile-tissue event in the priapism report reflects the sexual-function arm of that same signalling system (PMID 30796078).

Limits of the evidence in Module 4

Case reports establish that an event occurred in temporal association with exposure; they cannot establish incidence, causality, dose-dependence or susceptibility. There is no denominator — the number of people using these products is unknown — so no rate of priapism, infarction or dermatological harm can be derived. Products described in case reports were not analytically verified in the abstracts summarised here, so contaminants or mislabelling cannot be excluded as contributors.

Module 5 — Pharmacokinetics where data exist

This module is short by necessity. The verified literature summarised in this course does not report human pharmacokinetic parameters for Melanotan-2: no absorption, distribution, half-life, clearance or bioavailability figures appear in these sources, and no dose–exposure relationship is described. What the literature does supply is the pharmacological reasoning behind ligand choice — the 2024 tool-compound paper discussed how agonist selectivity and receptor engagement determine whether a melanocortin ligand is suitable for a given experiment (PMID 39296259). Peptides of this general class are, as a chemical matter, not well suited to oral absorption, which is why experimental melanocortin work is conducted by parenteral or central routes in animals, as in the central melanocortin receptor study in lean rats (PMID 29566460) and the long-term CNS leptin–melanocortin activation study (PMID 33532666).

Limits of the evidence in Module 5

No pharmacokinetic number should be inferred for humans from any statement above. In the absence of published human PK data, duration of receptor activation, accumulation with repeated exposure and inter-individual variability are all unquantified in this evidence set.

Module 6 — Regulatory status, stated factually

Melanotan-2 is not an approved medicine. It has not been granted marketing authorisation as a tanning agent, a weight-management agent or a sexual-function agent by major regulators, and no approved-product labelling for it exists. Material bearing the name is typically labelled for research use only (RUO), a designation that denotes laboratory use and expressly excludes human or veterinary administration; RUO labelling carries no regulatory finding of safety, efficacy, identity or purity.

Melanocortin receptor pharmacology as a field is legitimate and active — the 2024 paper on recommended tool compounds exists precisely to standardise laboratory work on these receptors (PMID 39296259) — but the legitimacy of the receptor family does not transfer to unapproved peptides sold under its banner. Pharmacy compounding, where permitted, operates from defined bulk-substance and prescribing frameworks; an unapproved peptide without an established bulk-substance status does not sit inside those frameworks. Clinical publications describing melanotan exposure have arisen from products obtained outside regulated supply, as in the priapism report (PMID 30796078) and the renal infarction report (PMID 31953620). This is general regulatory information, not legal advice; rules differ by country and change over time.

Limits of the evidence in Module 6

Regulatory status describes what agencies have and have not authorised. It says nothing about pharmacology, and a compound's absence from approved lists is neither evidence of danger nor evidence of hidden efficacy. Status also varies by jurisdiction and date, so any regulatory statement is a snapshot.

What the studies did not test

Across the entire evidence set summarised here, the following questions were not addressed:

1. Human efficacy for pigmentation. No controlled human trial of Melanotan-2 measuring skin pigment endpoints appears in these sources; the 2017 review addressed self-tanning and sunless tanning products as a category rather than testing this peptide (PMID 28823805).
2. Skin cancer risk over time. No long-term melanoma or keratinocyte-cancer follow-up exists in this set; the 2022 review addressed the circulation of skin cancer misinformation rather than incidence after peptide exposure (PMID 35514125).
3. Human body-weight or metabolic outcomes. The metabolic findings here came from rodent and genetic models such as the POMC-deficiency work (PMID 32244188) and the 5-HT2CR loss-of-function model (PMID 38815086).
4. Cardiovascular safety in people. The cardiac finding in this set was a rodent post-infarction restoration study of CNS leptin–melanocortin activation (PMID 33532666), not a human safety trial.
5. Sexual-function efficacy. The erectile dysfunction source here was a 2003 therapy review of the options of its era (PMID 14569381), not a trial of this peptide.
6. Inflammatory or ocular indications in humans. The uveitis work was an experimental autoimmune model using melanocortin receptor agonists (PMID 35196505).
7. Dosing, duration, interactions, pregnancy, paediatric exposure and product quality. None of these were studied in the sources reviewed, which is why no dosing information appears on this page.

The honest summary of this course is that Melanotan-2 has a well-described receptor mechanism, an animal literature about the melanocortin pathway rather than about the compound's popular uses, and a human literature made of individual adverse-event reports such as priapism (PMID 30796078) and renal infarction (PMID 31953620). Readers evaluating claims about this peptide can usefully ask, of any specific assertion, which of those three literatures it actually comes from.

References

• Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs) (ACS Pharmacology & Translational Science, 2024)
• Melanotan-induced priapism: a hard-earned tan (BMJ Case Reports, 2019)
• Melanotan II: a possible cause of renal infarction: review of the literature and case report (CEN Case Reports, 2020)
• [Self-tanning and sunless tanning products] (Annales de Dermatologie et de Vénéréologie, 2017)
• A qualitative review of misinformation and conspiracy theories in skin cancer (Clinical and Experimental Dermatology, 2022)
• Hypothalamic POMC deficiency increases circulating adiponectin despite obesity (Molecular Metabolism, 2020)
• Therapeutic Strategies Against Metabolic Imbalance in a Male Mouse Model With 5-HT2CR Loss-of-Function (Endocrinology, 2024)
• Melanocortin receptor agonists suppress experimental autoimmune uveitis (Experimental Eye Research, 2022)
• Inherently Lean Rats Have Enhanced Activity and Skeletal Muscle Response to Central Melanocortin Receptors (Obesity, 2018)
• Restoration of Cardiac Function After Myocardial Infarction by Long-Term Activation of the CNS Leptin-Melanocortin System (JACC: Basic to Translational Science, 2021)
• [Therapy of erectile dysfunction in 2005] (Der Urologe A, 2003)